NASDAQ, TSX: NVCN
VANCOUVER, March 21, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.
Conference Call & Webcast
Wednesday, March 28th @ 4:30pm Eastern Time
Domestic: | 800-281-7973 |
International: | 323-794-2093 |
Passcode: | 4395026 |
Webcast: | |
Replays available through April 10: | |
Domestic: | 844-512-2921 |
International: | 412-317-6671 |
Conference ID: | 4395026 |
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2018/21/c2027.html
Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568Copyright CNW Group 2018